TY  - JOUR
A1  - Witzel, Isabell
A1  - Müller, Volkmar
A1  - Abenhardt, Wolfgang
A1  - Kaufmann, Manfred
A1  - Schoenegg, Winfried
A1  - Schneeweis, Andreas
A1  - Jänicke, Fritz
T1  - Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer : results from the HER-OS patient registry
T2  - BMC cancer
N2  - Background: In this study, we examined patients who had non-progressive disease for at least 2 years after diagnosis of inoperable locoregional recurrent or metastatic breast cancer under continuous trastuzumab treatment. Our primary goal was to assess the long-term outcome of patients with durable response to trastuzumab.
Methods: 268 patients with HER2-positive inoperable locally recurrent or metastatic breast cancer and non-progressive disease for at least 2 years under trastuzumab treatment were documented retrospectively or prospectively in the HER-OS registry, an online documentation tool, between December 2006 and September 2010 by 71 German oncology centers. The study end point was time to tumor progression.
Results: Overall, 47.1% of patients (95% confidence interval (CI): 39.9–54.1%) remained in remission for more than 5 years, while the median time to progression was 4.5 years (95% CI: 4.0–6.6 years). Lower age (<50 years) and good performance status (ECOG 0) at time of trastuzumab treatment initiation as well as complete remission after initial trastuzumab treatment were associated with longer time to progression. Interruption of trastuzumab therapy correlated with shorter time to progression.
Conclusions: HER2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a long-term tumor remission of several years.
KW  - HER2
KW  - Metastatic breast cancer
KW  - Trastuzumab
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/38012
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-380125
SN  - 1471-2407
N1  - © 2014 Witzel et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
VL  - 14
IS  - 806
SP  - 1
EP  - 7
PB  - BioMed Central
CY  - London
ER  -